{"entity":{"id":"rec-4881","kind":"drug","name":"REC-4881","aka":[],"tldr":"REC-4881 is an experimental small molecule, allosteric MEK1/2 inhibitor from Recursion Pharmaceuticals, in phase 2 trials for familial adenomatous polyposis.","summary":"REC-4881 is a small molecule, allosteric MEK1/2 inhibitor (oral) from Recursion Pharmaceuticals. An orally bioavailable, non-ATP-competitive, allosteric inhibitor of MEK1 and MEK2, developed to reduce polyp burden and progression to adenocarcinoma in familial adenomatous polyposis. Its furthest stage is phase 2, for familial adenomatous polyposis (cancer predisposition; prevention of colorectal and upper GI adenocarcinoma). ClinicalTrials.gov registers it in 2 studies linked below. Pipeline page: 'Status: Phase 2', Fast Track and US/EU Orphan Drug. Registry: NCT05552755 (TUPELO, phase 1/2, FAP) recruiting; NCT06005974 (AXIN1/APC-mutant solid tumours, phase 2) terminated. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Recursion Pharmaceuticals: recursion.com","url":"https://www.recursion.com/pipeline"},{"label":"Recursion Pharmaceuticals: recursion.com","url":"https://www.recursion.com/pipeline"},{"label":"ClinicalTrials.gov: trials of REC-4881","url":"https://clinicaltrials.gov/search?intr=REC-4881"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["fap-associated-colorectal-cancer"],"sections":[],"technologies":[],"targets":["mek"],"drugs":[],"companies":["recursion"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05552755","nct06005974"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"REC-4881","modality":"Small molecule, allosteric MEK1/2 inhibitor (oral)","mechanism":"An orally bioavailable, non-ATP-competitive, allosteric inhibitor of MEK1 and MEK2, developed to reduce polyp burden and progression to adenocarcinoma in familial adenomatous polyposis.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rec-4881/","neighbours":{"cancer":[{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/"}],"target":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"}],"company":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/"}],"trial":[{"id":"nct06005974","kind":"trial","name":"A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation","route":"/trials/nct06005974/"},{"id":"nct05552755","kind":"trial","name":"Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)","route":"/trials/nct05552755/"}]}}